Polyglutamic Acid vs Hyaluronic Acid: Clinical Evidence and the Hyaluronidase Question

Polyglutamic acid and hyaluronic acid are routinely positioned as competitors on the skincare aisle, but the clinical literature does not actually support that framing. They are different molecules operating in different anatomical zones, with different mechanisms, and with different evidence profiles. The most interesting comparison is not whose hydration number is bigger. It is the hyaluronidase question — whether gamma-PGA's documented ability to inhibit the enzyme that degrades endogenous HA reframes the entire layering conversation. This piece walks through the molecular-weight reasoning, the enzymology, the controlled-trial data, and the layering protocol the evidence actually supports.

What Each Polymer Actually Is — and Why That Determines Behavior

Gamma-polyglutamic acid is a fermentation-derived polypeptide produced by Bacillus subtilis natto, the same bacterial strain responsible for the traditional Japanese soybean ferment, and in topical formulations it is delivered at molecular weights typically exceeding 1,000 kilodaltons — an order of magnitude above even the highest-MW hyaluronic acid fractions used in skincare. That size determines its anatomical destination. PGA at 1,000 to 2,000 kDa cannot penetrate the stratum corneum, which selectively excludes molecules above roughly 500 daltons; the polymer instead deposits at the skin surface and forms a flexible, breathable hydrogel film as it interacts with ambient and residual moisture.

Hyaluronic acid is structurally different. It is a glycosaminoglycan composed of repeating disaccharide units of glucuronic acid and N-acetylglucosamine, and in commercial skincare it is supplied across a wide molecular weight spectrum — from oligomeric fragments below 10 kDa to high-MW preparations above 1,500 kDa. That spectrum matters clinically. Low-molecular-weight HA fractions, generally between 10 and 50 kDa, can cross the stratum corneum and reach the viable epidermis where they hydrate from within. High-MW HA, by contrast, behaves more like PGA, sitting at the surface and pulling moisture from the surrounding atmosphere and underlying tissue.

The implication is that PGA and HA are not competing for the same job. PGA is a single-zone surface humectant by design; HA is a multi-zone humectant whose anatomical destination depends entirely on which molecular weight fraction a formulator selects. Comparing them as if they were interchangeable obscures the more useful clinical question — which mechanism does a given skin state actually need.

The Hyaluronidase Question: Why PGA's Most Interesting Property Is Enzymatic

Hyaluronidase is a family of enzymes that catalyzes the hydrolysis of hyaluronic acid, cleaving the polymer's beta-1,4 glycosidic bonds and breaking long-chain HA into progressively smaller, less functional fragments — and gamma-polyglutamic acid has been documented in in vitro work to inhibit hyaluronidase activity, a finding that, if it translates to topical application, would slow the degradation of the HA the skin produces endogenously.

The dermatological relevance of this is underappreciated. Endogenous HA in the dermis turns over on a timescale of roughly one day, with hyaluronidase activity setting much of the upper bound on that half-life. Anything that meaningfully inhibits hyaluronidase in the relevant tissue would extend the functional lifetime of the HA the skin makes for itself, independent of any HA a topical product supplies. The peer-reviewed Korean cosmetic-science literature, where much of the early gamma-PGA work originated, repeatedly documents this inhibition signal in cell-free and cell-culture systems.

The translation question is genuine and worth stating plainly. In vitro hyaluronidase inhibition does not automatically prove dermal-level inhibition from a topical surface application, particularly when the polymer in question is too large to cross the stratum corneum. Whether the effect propagates inward via diffusion of smaller PGA fragments, indirect signaling, or sustained surface enzyme inhibition that protects HA in the upper layers of the epidermis is an active research question. What is defensible to say is that the mechanism is biologically plausible, the in vitro evidence is consistent across multiple labs, and the in vivo translation has not yet been characterized at the rigor a regulator would require for a drug claim.

For a science-forward reader, the appropriate framing is: hyaluronidase inhibition is the property that distinguishes PGA from a generic surface humectant. It is also the property whose clinical translation requires more data than currently exists. Both statements can be true at once.

The Controlled-Trial Data: What the Clinical Evidence Actually Shows

In the most-cited comparative trial, a gamma-PGA preparation maintained roughly 45 percent water retention at the 120-minute mark following a single application, compared with approximately 36 percent for a hyaluronic acid preparation tested under matched conditions — a directional finding that has been broadly cited but that comes from a study with modest sample size and industry funding.

The clinical evidence base for PGA falls into three categories. The first is the small-sample comparative in vivo work, of which the 45-versus-36 percent result is representative. These studies typically involve fewer than fifty participants, single-application or short-duration protocols, and instrumentation that measures TEWL or surface conductance as a proxy for hydration. The findings are internally consistent and point in the same direction: PGA outperforms HA on sustained surface moisture metrics over short timeframes. They are not yet at the sample size and independence level that conventional dermatological practice treats as definitive.

The second category is the in vitro enzymology and skin-equivalent work that underpins the hyaluronidase claim. This literature is well-replicated within its category but has not been bridged to in vivo dermal endpoints in a way that satisfies translational rigor. The third category is the formulation-stability and barrier-function literature, which documents PGA's compatibility with common cosmetic systems and its capacity to stimulate keratinocyte production of natural moisturizing factor components — a finding that, if confirmed at scale, would situate PGA as more than a passive surface film.

The honest synthesis is that the evidence base for gamma-PGA is real, internally consistent, and pointed in a favorable direction, while remaining smaller and less independent than the evidence base for hyaluronic acid, which has accumulated multi-decade clinical use across cosmetic and medical applications. A reader weighing the two should treat the directional findings as credible and the magnitude of advantage as not yet precisely established.

Formulation Considerations: What Determines Whether the Mechanism Lands

The clinical performance of gamma-PGA depends substantially on formulation specifics that consumer marketing rarely discloses, and a serum that lists PGA on its INCI deck delivers very different outcomes depending on concentration, molecular weight grade, pH window, and the supporting vehicle. Functional concentrations in published clinical work typically fall between 0.1 and 2 percent, with 0.5 to 1 percent representing the most commonly tested range. Below 0.1 percent, the film-forming behavior that drives the TEWL reduction begins to fall apart.

Molecular weight grade is the second variable. PGA above approximately 1,000 kDa behaves as the surface-zone humectant the comparative trials evaluated; preparations below that range — sometimes used in industrial or agricultural applications — do not necessarily reproduce the same skin behavior. Reputable cosmetic formulators specify gamma-PGA explicitly and frequently disclose the molecular weight grade in technical documentation, even when consumer-facing copy does not.

Compatibility is the third. Gamma-PGA carries a negative charge at typical skincare pH and can form complexes with cationic ingredients, which can either stabilize a formulation or precipitate depending on the system. Pairing PGA with low-pH actives — high-percentage AHAs, low-pH vitamin C — requires careful formulation work because acidic conditions can compromise the film's integrity. None of this is exotic; it simply means the ingredient does not deliver identical performance across every product that lists it.

The Layering Protocol the Evidence Supports

Because PGA and HA operate in different anatomical zones, the strongest hydration strategy for most skin types is to apply both rather than choose between them — with the order and the molecular-weight selection determined by the mechanism each ingredient is being asked to perform. On damp skin, a low-molecular-weight hyaluronic acid serum penetrates the upper layers of the viable epidermis and binds water within the tissue. Layered on top, a gamma-PGA serum or finishing product forms a surface film that slows the rate at which that water — and the moisture endogenously produced by the skin — escapes into the environment.

This sequencing addresses the most common functional failure of high-MW HA-only routines in low-humidity conditions, which is that surface HA can reverse-osmose moisture from the dermis when ambient humidity is insufficient to supply it. Adding a PGA film on top mitigates that reversal by reducing the moisture gradient at the surface. It also lengthens the effective hydration window: short-duration trials suggest the PGA film extends measurable surface moisture for several hours beyond what single-ingredient HA preparations deliver, particularly in dry-air conditions.

For sensitive or barrier-compromised skin, the same logic applies but with additional caution about supporting ingredients. PGA itself has a low irritation profile across published safety work, and HA is well-tolerated across skin types, but combination products often include preservatives, fragrances, or supporting humectants that can drive reactivity independent of the headline actives. Patch testing remains advisable when introducing any new layered routine, and the marketing language of a product matters less than its actual INCI deck.

Frequently Asked Questions

What does hyaluronidase do, and why does it matter for skincare?

Hyaluronidase is a family of enzymes that depolymerize hyaluronic acid, breaking the long-chain polymer the skin uses to retain water into smaller, less-functional fragments. Endogenous hyaluronidase activity is one reason topical and dermal HA has a finite functional half-life. In vitro work suggests gamma-PGA can inhibit hyaluronidase activity, which would slow the degradation of HA the skin already produces, though clinical translation to topical use is still being characterized.

Is polyglutamic acid better than hyaluronic acid?

The framing is misleading. Controlled comparisons show gamma-PGA outperforms HA on sustained surface hydration metrics like transepidermal water loss reduction at 120 minutes, but HA penetrates the viable epidermis at low molecular weights in a way PGA does not. They occupy different anatomical zones. The clinically defensible position is that they are complementary, not interchangeable.

Can I layer polyglutamic acid and hyaluronic acid together?

The mechanism rationale supports layering: PGA forms a film at the surface that slows water loss while low-MW HA penetrates more deeply. Most consumer routines apply low-MW HA first to damp skin, then PGA on top to seal the surface. Direct comparative trials of layered versus single-ingredient regimens are still limited, so the evidence is best described as mechanistically supported rather than head-to-head proven.

What molecular weight of polyglutamic acid is used in skincare?

Gamma-PGA in topical products typically exceeds 1,000 kilodaltons, frequently in the range of 1,000 to 2,000 kDa. This high molecular weight is intentional — it ensures the polymer cannot cross the stratum corneum and instead forms a surface film. Lower-MW PGA fractions exist in industrial applications but are not standard in skincare formulations marketed for moisture retention.

Are there clinical trials directly comparing PGA and HA?

A small number of controlled in vivo comparisons have been published; the most-cited shows gamma-PGA achieving roughly 45 percent water retention at 120 minutes versus approximately 36 percent for HA under matched conditions. Sample sizes are modest, study durations short, and many published comparisons are industry-funded. The directional finding — PGA edges HA on sustained surface moisture retention — is consistent, but the evidence base is still maturing.

The Verdict

The clinical evidence does not support a winner-takes-all framing of polyglutamic acid versus hyaluronic acid, and the comparison most worth making is the one the marketing rarely makes. PGA's distinguishing property is not the percentage point of hydration advantage in a 120-minute test. It is the in vitro hyaluronidase inhibition that, if translated to topical use, would extend the functional lifetime of the HA the skin produces for itself. That mechanism is biologically plausible, repeatedly observed in cell-free systems, and not yet rigorously characterized in vivo. The practical synthesis is straightforward: apply low-molecular-weight HA to damp skin, layer gamma-PGA on top to seal the surface, and treat the comparative literature as directional rather than definitive while the independent RCT base continues to mature.